Evvy, a women’s health startup founded in 2021 by Priyanka Jain, Laine Bruzek, and Pita Navarro, recently closed a $40 million Series B funding round led by Catalio Capital Management. The company operates what it claims to be the world’s only at-home, CLIA- and CLEP-certified metagenomic next-generation sequencing (mNGS) test that analyzes vaginal microbiomes from a single swab. Users send samples to Evvy's lab for sequencing, after which results are reviewed by clinicians and made available through an online health portal, complete with diagnostic interpretations and personalized next steps including prescription options when applicable.

Since its inception, Evvy has served over 100,000 patients and partnered with 3,000 healthcare providers across the United States. The company has contributed to the scientific field by publishing 15 peer-reviewed papers, identifying new bacterial vaginosis subtypes, and uncovering hundreds of previously undocumented vaginal microbiome genomes. The data collected not only supports personalized treatment but also fuels Evvy's broader vision to build a comprehensive database that links microbiome biology with symptoms, treatments, and health outcomes to enhance care and discover novel biomarkers.

Evvy recognizes a critical gap in women's health research due to the historical lack of robust biological data on female bodies, which hinders the development of precise medical interventions. To address this, the company launched EvvyAI in May, an AI-powered companion that interprets microbiome data and provides real-time health guidance, referring patients to clinicians when necessary. Expanding beyond vaginal health, Evvy is venturing into fertility research, exploring how vaginal microbiomes correlate with infertility, gynecologic cancers, IVF success, and pregnancy complications, with ongoing studies in IVF clinics.

Priyanka Jain hopes that Evvy's approach will eventually lead to a modern replacement for the Pap smear—an easy, non-invasive at-home test offering detailed insights across a wide range of women's health conditions, from infections to hormonal changes and cancer risk. Jain emphasizes the importance of accelerating research with patient-driven data collection rather than waiting for traditional studies to catch up, aiming to transform unexplained symptoms and fertility challenges into actionable medical knowledge that benefits women broadly.